Use: Labeled indications
- INDICATIONS AND USAGE Magnesium Sulfate Injection, USP is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in…
Full indications and usage US FDA label
INDICATIONS AND USAGE Magnesium Sulfate Injection, USP is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. In such cases, the serum magnesium level is usually below the lower limit of normal (1.5 to 2.5 mEq/L) and the serum calcium level is normal (4.3 to 5.3 mEq/L) or elevated.
In total parenteral nutrition (TPN), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. Magnesium sulfate injection is also indicated for the prevention and control of seizures in a pre-eclampsia and eclampsia, respectively.
Contraindications
CONTRAINDICATIONS Parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION Dosage of magnesium sulfate must be carefully adjusted according to individual requirements and response, and administration of the drug should be discontinued as soon as the desired effect is obtained. Both IV and IM administration are appropriate. IM administration of the undiluted 50% solution results in therapeutic plasma levels in 60 minutes, whereas IV doses will provide a therapeutic level almost immediately.
The rate of IV injection should generally not exceed 150 mg/minute (1.5 mL of a 10% concentration or its equivalent), except in severe eclampsia with seizures (see below). Continuous maternal administration of magnesium sulfate in pregnancy beyond 5 to 7 days can cause fetal abnormalities. Solutions for IV infusion must be diluted to a concentration of 20% or less prior to administration.
The diluents commonly used are 5% Dextrose Injection, USP and 0.9% Sodium Chloride Injection, USP. Deep IM injection of the undiluted (50%) solution is appropriate for adults, but the solution should be diluted to a 20% or less concentration prior to such injection in children. In Magnesium Deficiency In the treatment of mild magnesium deficiency, the usual adult dose is 1 g, equivalent to 8.12 mEq of magnesium (2 mL of the 50% solution) injected IM every six hours for four doses (equivalent to a total of 32.5 mEq of magnesium per 24 hours).
For severe hypomagnesemia, as much as 250 mg (approximately 2 mEq) per kg of body weight (0.5 mL of the 50% solution) may be given IM within a period of four hours if necessary. Alternatively, 5 g (approximately 40 mEq) can be added to one liter of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP for slow IV infusion over a three-hour period.
In the treatment of deficiency states, caution must be observed to prevent exceeding the renal excretory capacity. In Hyperalimentation In TPN, maintenance requirements for magnesium are not precisely known. The maintenance dose used in adults ranges from 8 to 24 mEq (1 to 3 g) daily; for infants, the range is 2 to 10 mEq (0.25 to 1.25 g) daily.
In Pre-eclampsia or Eclampsia In severe pre-eclampsia or eclampsia, the total initial dose is 10 to 14 g of magnesium sulfate. Intravenously, a dose of 4 to 5 g in 250 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP may be infused. Simultaneously, IM doses of up to 10 g (5 g or 10 mL of the undiluted 50% solution in each buttock) are given.
Alternatively, the initial IV dose of 4 g may be given by diluting the 50% solution to a 10 or 20% concentration; the diluted fluid (40 mL of a 10% solution or 20 mL of a 20% solution) may then be injected IV over a period of three to four minutes. Subsequently, 4 to 5 g (8 to 10 mL of the 50% solution) are injected IM into alternate buttocks every four hours as needed, depending on the continuing presence of the patellar reflex and adequate respiratory function.
Alternatively, after the initial IV dose, some clinicians administer 1 to 2 g/hour by constant IV infusion. Therapy should continue until paroxysms cease. A serum magnesium level of 6 mg/100 mL is considered optimal for control of seizures. A total daily (24 hr) dose of 30 to 40 g should not be exceeded. In the presence of severe renal insufficiency, the maximum dosage of magnesium sulfate is 20 grams/48 hours and frequent serum magnesium concentrations must be obtained.
Continuous use of magnesium sulfate in pregnancy beyond 5 to 7 days can cause fetal abnormalities. Other uses In counteracting the muscle-stimulating effects of barium poisoning, the usual dose of magnesium sulfate is 1 to 2 g given IV. For controlling seizures associated with epilepsy, glomerulonephritis or hypothyroidism, the usual adult dose is 1 g administered IM or IV.
In paroxysmal atrial tachycardia, magnesium should be used only if simpler measures have failed and there is no evidence of myocardial damage. The usual dose is 3 to 4 g (30 to 40 mL of a 10% solution) administered IV over 30 seconds with extreme caution. For reduction of cerebral edema, 2.5 g (25 mL of a 10% solution) is given IV.
Incompatibilities Magnesium sulfate in solution may result in a precipitate formation when mixed with solutions containing: Alcohol (in high concentrations) Heavy metals Alkali carbonates and bicarbonates Hydrocortisone sodium succinate Alkali hydroxides Phosphates Arsenates Polymyxin B sulfate Barium Procaine hydrochloride Calcium Salicylates Clindamycin phosphate Strontium Tartrates The potential incompatibility will often be influenced by the changes in the concentration of reactants and the pH of the solutions. It has been reported that magnesium may reduce the antibiotic activity of streptomycin, tetracycline and tobramycin when given together.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
In Magnesium Deficiency In the treatment of mild magnesium deficiency, the usual adult dose is 1 g, equivalent to 8.12 mEq of magnesium (2 mL of the 50% solution) injected IM every six hours for four doses (equivalent to a total of 32.5 mEq of magnesium per 24 hours). For severe hypomagnesemia, as much as 250 mg (approximately 2 mEq) per kg of body weight (0.5 mL of the 50% solution) may be given IM within a period of four hours if necessary.
Alternatively, 5 g (approximately 40 mEq) can be added to one liter of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP for slow IV infusion over a three-hour period. In the treatment of deficiency states, caution must be observed to prevent exceeding the renal excretory capacity.
In Hyperalimentation In TPN, maintenance requirements for magnesium are not precisely known. The maintenance dose used in adults ranges from 8 to 24 mEq (1 to 3 g) daily; for infants, the range is 2 to 10 mEq (0.25 to 1.25 g) daily.
In Pre-eclampsia or Eclampsia In severe pre-eclampsia or eclampsia, the total initial dose is 10 to 14 g of magnesium sulfate. Intravenously, a dose of 4 to 5 g in 250 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP may be infused. Simultaneously, IM doses of up to 10 g (5 g or 10 mL of the undiluted 50% solution in each buttock) are given.
Alternatively, the initial IV dose of 4 g may be given by diluting the 50% solution to a 10 or 20% concentration; the diluted fluid (40 mL of a 10% solution or 20 mL of a 20% solution) may then be injected IV over a period of three to four minutes. Subsequently, 4 to 5 g (8 to 10 mL of the 50% solution) are injected IM into alternate buttocks every four hours as needed, depending on the continuing presence of the patellar reflex and adequate respiratory function.
Alternatively, after the initial IV dose, some clinicians administer 1 to 2 g/hour by constant IV infusion. Therapy should continue until paroxysms cease. A serum magnesium level of 6 mg/100 mL is considered optimal for control of seizures. A total daily (24 hr) dose of 30 to 40 g should not be exceeded. In the presence of severe renal insufficiency, the maximum dosage of magnesium sulfate is 20 grams/48 hours and frequent serum magnesium concentrations must be obtained.
Continuous use of magnesium sulfate in pregnancy beyond 5 to 7 days can cause fetal abnormalities.
Other uses In counteracting the muscle-stimulating effects of barium poisoning, the usual dose of magnesium sulfate is 1 to 2 g given IV. For controlling seizures associated with epilepsy, glomerulonephritis or hypothyroidism, the usual adult dose is 1 g administered IM or IV. In paroxysmal atrial tachycardia, magnesium should be used only if simpler measures have failed and there is no evidence of myocardial damage.
The usual dose is 3 to 4 g (30 to 40 mL of a 10% solution) administered IV over 30 seconds with extreme caution. For reduction of cerebral edema, 2.5 g (25 mL of a 10% solution) is given IV.
Incompatibilities Magnesium sulfate in solution may result in a precipitate formation when mixed with solutions containing: Alcohol (in high concentrations) Heavy metals Alkali carbonates and bicarbonates Hydrocortisone sodium succinate Alkali hydroxides Phosphates Arsenates Polymyxin B sulfate Barium Procaine hydrochloride Calcium Salicylates Clindamycin phosphate Strontium Tartrates The potential incompatibility will often be influenced by the changes in the concentration of reactants and the pH of the solutions. It has been reported that magnesium may reduce the antibiotic activity of streptomycin, tetracycline and tobramycin when given together.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Dosing: Altered kidney function
In the treatment of deficiency states, caution must be observed to prevent exceeding the renal excretory capacity.
In the presence of severe renal insufficiency, the maximum dosage of magnesium sulfate is 20 grams/48 hours and frequent serum magnesium concentrations must be obtained.
In the treatment of deficiency states, caution must be observed to prevent exceeding the renal excretory capacity.
In the presence of severe renal insufficiency, the maximum dosage of magnesium sulfate is 20 grams/48 hours and frequent serum magnesium concentrations must be obtained.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- Solution for injection: 250 mg/mL, 500 mg/mL
- ) solution for injection: 500 mg/mL (10 g/20 mL
- Solution f or injection: 250 mg/mL
Registered products in the Philippines
13 products registered with the Food and Drug Administration (FDA) Philippines list Magnesium sulfate as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Magnesium sulf ate (as heptahydrate) (1 product) · Magnesium Sulfate Heptahydrate (1 product). Products registered under these spellings are included in the table and marked.
All registered products13
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
250 mg/mL Solution f or Injection (IM/IV)Type-I Clear Glass Ampoule x 10 mL (Box of 1's, 5's, 10's, 50's, and 100's) | Rx | Cotec Healthcare Pvt. Ltd.India | Despina Pharma Inc. | DRP-18426 | Jul 8, 2031 | ||
EpsiumMagnesium Sulfate | 250 mg/mL Solution for injection (I.M./I.V.)10 mL USP Type I Clear Glass Ampoule (Box of 5's) | Rx | Shanghai Xudong Haipu Pharmaceutical Co., Ltd.China | Endure Medical Inc. | DR-XY42998 | Nov 22, 2028 | |
MagnevoxMagnesium Sulfate | 250 mg/mL Solution for Injection (IM/IV)10 mL and 20 mL polypropylene ampoule in a plastic tray (Box of 10's) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | PhilRx Pharma Inc. | DRP-18512 | Jul 27, 2031 | |
NoneMagnesium Sulfate | 250 mg/mL (25 %) Solution for Injection (I.M. /I.V.)10 mL Type I Clear Vial with Rubber Stopper & Aluminum Flip-off Seal (Box of 10's) | Rx | EL Laboratories, Inc.Philippines | Trader: Elin Pharmaceuticals, Inc. | DR-XY22960 | Jun 3, 2027 | |
NoneMagnesium Sulfate | 250 mg/mL (25%) Solution for Injection (IM/IV)Low Density Polyethylene Plastic Vial with rubber stopper x 20 mL (Box of 20's) | Rx | Euro-Med Laboratories Phil., Inc.Philippines | — | DR-XY 19745 | May 25, 2030 | |
250 mg/mL Solution for Injection (I.M./I.V.)Amber Glass Ampoule x 10 mL Box of 100’s | Rx | Hizon Laboratories, Inc.Philippines | — | DR-5362 | May 9, 2031 | ||
NoneMagnesium Sulfate (as heptahydrate) | 250 mg/mL Solution for Injection (I.M./I.V.)Glass Ampule x 10 mL Box of 25's | Rx | HARSON LABORATORIESIndia | PHIL. PHARMAWEALTH, INC. | DR-XY23323 | Sep 19, 2027 | |
noneMagnesium Sulfate | 250 mg/mL Solution for Injection (I.M./I.V.)10 mL and 20 mL polypropylene ampoule (Box of 10's) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | PhilRx Pharma Inc. | DRP-12981 | Nov 18, 2027 | |
NoneMagnesium Sulfate | 500 mg/mL Solution for Injection (I.M./I.V.)Amber Colored Type I Glass Ampoule x 2 mL (Box of 100’s) | Rx | Hizon Laboratories, Inc.Philippines | — | DR-5361 | Aug 21, 2031 | |
NoneMagnesium Sulfate (as heptahydrate) | 500 mg/mL Solution for Injection (I.M./I.V.)Clear glass ampoule x 2 mL (Box of 50's) | Rx | Atlantic Laboratories Corporation Ltd.Thailand | Phil Pharmawealth, Inc. | DR-XY27840 | Sep 19, 2027 | |
RahmasulMagnesium Sulfate | 500 mg/mL Solution for Injection (IM/IV)Type I Amber Glass Ampoule x 10 mL (Box of 10's) | Rx | Maxitech Pharma (Pvt) Ltd.Pakistan | Accesspoint International Trading Inc. | DRP-16888 | Aug 7, 2030 | |
RanesiumMagnesium Sulfate | 250 mg/mL Solution For Injection (I.M/I.V.)20 mL-Capacity type I Clear Glass vial Sealed with Rubber Stopper and Aluminum Flip-off Cap x 10 mL (Net content) (Box of 10's) | Rx | Jiangsu Ruinian Qianjin Pharmaceutical Co., Ltd.China | Raquel Abbas Pharma Inc. | DRP-19038 | Oct 21, 2031 | |
(no brand name)Magnesium sulfate (as heptahydrate) | 500 mg/ mL (10 g/20 mL) Solution for Injection (I.M./I.V.)Polypropylene plastic ampoule x 20 mL (net content) (Box of 50's) | Rx | Dai Han Pharm Co., Ltd.Korea | JLT Pharma, Inc. | DRP-11096 | Jan 28, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS FETAL HARM: Continuous administration of magnesium sulfate beyond 5 to 7 days to pregnant women can lead to hypocalcemia and bone abnormalities in the developing fetus. These bone abnormalities include skeletal demineralization and osteopenia. In addition, cases of neonatal fracture have been reported. The shortest duration of treatment that can lead to fetal harm is not known.
Magnesium sulfate should be used during pregnancy only if clearly needed. If magnesium sulfate is given for treatment of preterm labor, the woman should be informed that the efficacy and safety of such use have not been established and that use of magnesium sulfate beyond 5 to 7 days may cause fetal abnormalities. ALUMINUM TOXICITY: This product contains aluminum that may be toxic.
Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity.
Tissue loading may occur at even lower rates of administration. Parenteral use in the presence of renal insufficiency may lead to magnesium intoxication. IV use in eclampsia should be reserved for immediate control of life-threatening convulsions.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS The adverse effects of parenterally administered magnesium usually are the result of magnesium intoxication. These include flushing, sweating, hypotension, depressed reflexes, flaccid paralysis, hypothermia, circulatory collapse, cardiac and CNS depression proceeding to respiratory paralysis. Hypocalcemia with signs of tetany secondary to magnesium sulfate therapy for eclampsia has been reported.
Pharmacokinetics
Magnesium is excreted solely by the kidneys at a rate proportional to the plasma concentration and glomerular filtration.
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY Magnesium is an important cofactor for enzymatic reactions and plays an important role in neurochemical transmission and muscular excitability. As a nutritional adjunct in hyperalimentation, the precise mechanism of action for magnesium is uncertain. Early symptoms of hypomagnesemia (less than 1.5 mEq/L) may develop as early as three to four days or within weeks.
Predominant deficiency effects are neurological, e.g., muscle irritability, clonic twitching and tremors. Hypocalcemia and hypokalemia often follow low serum levels of magnesium. While there are large stores of magnesium present intracellularly and in the bones of adults, these stores often are not mobilized sufficiently to maintain plasma levels.
Parenteral magnesium therapy repairs the plasma deficit and causes deficiency symptoms and signs to cease. Magnesium prevents or controls convulsions by blocking neuromuscular transmission and decreasing the amount of acetylcholine liberated at the end-plate by the motor nerve impulse. Magnesium is said to have a depressant effect on the central nervous system (CNS), but it does not adversely affect the woman, fetus or neonate when used as directed in eclampsia or pre-eclampsia.
Normal plasma magnesium levels range from 1.5 to 2.5 mEq/L. As plasma magnesium rises above 4 mEq/L, the deep tendon reflexes are first decreased and then disappear as the plasma level approaches 10 mEq/L. At this level respiratory paralysis may occur. Heart block also may occur at this or lower plasma levels of magnesium.
Serum magnesium concentrations in excess of 12 mEq/L may be fatal. Magnesium acts peripherally to produce vasodilation. With low doses only flushing and sweating occur, but larger doses cause lowering of blood pressure. The central and peripheral effects of magnesium poisoning are antagonized to some extent by IV administration of calcium.
Pharmacokinetics With IV administration the onset of anticonvulsant action is immediate and lasts about 30 minutes. Following IM administration, the onset of action occurs in about one hour and persists for three to four hours. Effective anticonvulsant serum levels range from 2.5 to 7.5 mEq/L. Magnesium is excreted solely by the kidneys at a rate proportional to the plasma concentration and glomerular filtration.
Pharmacokinetics With IV administration the onset of anticonvulsant action is immediate and lasts about 30 minutes. Following IM administration, the onset of action occurs in about one hour and persists for three to four hours. Effective anticonvulsant serum levels range from 2.5 to 7.5 mEq/L. Magnesium is excreted solely by the kidneys at a rate proportional to the plasma concentration and glomerular filtration.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Magnesium Sulfate 250 mg/mL, 10 mL Ampule | ₱18.72–₱57.88Reference ₱23.44 | per ampule | DPRI procurement range |
| Magnesium Sulfate 250 mg/mL, 10 mL Vial | ₱22.40–₱55.98Reference ₱29.16 | per vial | DPRI procurement range |
| Magnesium Sulfate 250 mg/mL, 20 mL Vial | ₱19.00–₱52.00Reference ₱28.60 | per vial | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Magnesium Sulfate (as heptahydrate) |
| PNF listing | Inj.: 250 mg/mL, 2 mL and 10 mL ampul (IM, IV)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PNF listing | Inj.: 250 mg/mL, 10 mL, 20 mL and 50 mL vial (IV)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PNF listing | Inj.: 500 mg/mL, 2 mL and 10 mL ampul (IM, IV)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Magnesium Sulfate · Fresenius Kabi USA, LLC [US FDA-approved label, version 5, January 13, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e921a46b-9a5b-4163-9c88-224247541f14
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .